Holding(s) in Company

26 March 2010

Akers Biosciences Inc.

(the "Company")

Holdings in Company

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, received notification on 26 March 2010 that, following the sale of 1,825,000 Common Shares, funds controlled by Southridge Capital Management LLC (Brittany Capital) now have an interest in the Company of 7,592,135 Common Shares, representing approximately 6.64 per cent. of the Company's issued share capital.

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

Emma Earl or Simon Leathers

Daniel Stewart & Co.

Tel. +44 (0)20 7776 6550